title: Hepatitis B and end-stage liver disease.
abstract: Hepatitis B virus (HBV) is the most common cause of chronic hepatitis and end-stage liver disease worldwide. Untreated, chronic hepatitis B acquired early in life results in cirrhosis, liver failure, or hepatocellular carcinoma in up to 40% of individuals. Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis. This article reviews recent advances in the understanding of the natural history, prevention, and medical management of HBV-related end-stage liver disease.
authors.affiliation: Division of Gastroenterology and Hepatology, New York Weill Cornell Medical Center, 525 E. 68th Street, New York, NY 10021, USA.
authors.forename: Ilan S
authors.initials: IS
authors.lastname: Weisberg
authors.forename: Robert S
authors.initials: RS
authors.lastname: Brown
authors.forename: Samuel H
authors.initials: SH
authors.lastname: Sigal
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006515:Hepatitis B virus / Q000254:growth & development*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications* / Q000517:prevention & control; D017093:Liver Failure / Q000517:prevention & control / Q000821:virology*; D008297:Male
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha